Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis Erre GL; Passiu GReumatismo 2009[Apr]; 61 (2): 90-7Many lines of independent research have pointed out the role of oxidative stress as a fascinating pathogenic link between the three main hallmarks of systemic sclerosis (SSc), viz. humoral and cellular immunity activation, microvascular damage and widespread tissue fibrosis. Therefore counteracting oxidative stress may have a favourable impact on clinical features and progression of disease. It is becoming clearer that Iloprost, a synthetic stable analogue of prostacycline, currently employed in the treatment of SSc vascular features, also possess anti-oxidative properties beside its prostaglandin-like vasodilatory and antiaggregant effects. This brief review is aimed to discuss available clinical evidences supporting Iloprost antioxidant action and focus on putative molecular pathways underlying it.|Antioxidants/pharmacology/*therapeutic use[MESH]|Evidence-Based Medicine[MESH]|Humans[MESH]|Iloprost/pharmacology/*therapeutic use[MESH]|Oxidative Stress/*drug effects[MESH]|Platelet Aggregation Inhibitors/therapeutic use[MESH]|Scleroderma, Systemic/*drug therapy/metabolism[MESH]|Superoxide Dismutase/drug effects[MESH]|Treatment Outcome[MESH]|Vasodilator Agents/pharmacology/*therapeutic use[MESH] |
